Ask AI

CCO Independent Conference Highlights From the 2025 ASCO Annual Meeting

Review slidesets, on-demand webcasts, an expert analysis, and a podcast of key data from the 2025 ASCO Annual Meeting.

Share

Program Content

Activities

ASCO 2025 Preview
An Expert’s Guide to ASCO 2025: Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 29, 2025

Expires: November 28, 2025

Events

Live Event
Conference to Clinic - Bridging Breast Cancer Discoveries to Practice
Congratulations: You achieved a completion on 04/09/2022

You can enroll in the following live event(s) on this topic.

Activities

EMBER 3 PROs
EMBER-3 Patient-Reported Outcomes: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After PD on Previous ET
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2025

Expires: December 01, 2025

ASCENT 04 KEYNOTE D19
ASCENT-04//KEYNOTE-D19: Phase III Trial of First-line Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–Positive Advanced TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2025

Expires: December 02, 2025

VERITAC 2
VERITAC-2: Phase III Study of Vepdegestrant vs Fulvestrant in Previously Treated ER-Positive/HER2-Negative Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2025

Expires: December 02, 2025

OptiTROP Breast05
OptiTROP-Breast05: Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) in the 1L Treatment of Unresectable Locally Advanced/Metastatic TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2025

Expires: December 02, 2025

SERENA 6
SERENA-6: Phase III Trial of ctDNA-Guided Switch to Camizestrant + CDK4/6i vs Continued AI + CDK4/6i Following ESR1 Mutation Emergence in HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2025

Expires: December 02, 2025

NATALEE Menopausal Analysis
NATALEE: Outcomes by Menopausal Status and Age From a Phase III Trial of Adjuvant Ribociclib + NSAI vs NSAI Alone in Patients With HR+/HER2- EBC 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2025

Expires: December 03, 2025

ELEVATE
ELEVATE: Preliminary Safety and Efficacy of Elacestrant in Combination With Everolimus or Ribociclib in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2025

Expires: December 03, 2025

INAVO120
INAVO120: OS From Phase III Study of 1L Inavolisib/PBO + Palbociclib + Fulvestrant in PIK3CA-Mutated, HR+/HER2-, Endocrine-Resistant Advanced Breast Cancer 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2025

Expires: December 03, 2025

DESTINY Breast09
DESTINY-Breast09: Phase III Trial of Trastuzumab Deruxtecan ± Pertuzumab vs THP as 1L Treatment of HER2+ Advanced/Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2025

Expires: December 03, 2025

OASIS-4
OASIS-4: Phase III Trial of Elinzanetant for Vasomotor Symptoms Associated With Endocrine Therapy in Patients With or at Risk for HR+ Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2025

Expires: December 05, 2025

neoCARHP
neoCARHP: Phase III Trial of De-escalated Neoadjuvant Taxane + Trastuzumab and Pertuzumab ± Carboplatin in HER2+ EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2025

Expires: December 09, 2025

EA1181 CompassHER2 pCR
EA1181/CompassHER2-pCR: Clinicopathologic Factors and Genomic Testing Associated With pCR After Adjuvant THP in Stage II-III HER2+ Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2025

Expires: December 09, 2025

Activities

ANCHOR
ANCHOR: Phase III Trial of Anlotinib or Bevacizumab With 1L Chemotherapy for RAS/BRAF Wild-Type Unresectable mCRC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2025

Expires: December 02, 2025

ATOMIC
ATOMIC: Phase III Trial of Adjuvant Chemotherapy ± Atezolizumab in Patients With Stage III Deficient DNA Mismatch Repair Colon Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2025

Expires: December 03, 2025

BREAKWATER
BREAKWATER: PFS From the Phase III Trial of 1L Encorafenib + Cetuximab + Chemotherapy vs SoC for BRAF V600E–Mutant mCRC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2025

Expires: December 03, 2025

MATTERHORN
MATTERHORN: Phase III Trial of Durvalumab or Placebo + FLOT in Resectable Gastric and Gastroesophageal Junction Cancers
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2025

Expires: December 04, 2025

DESTINY Gastric04
DESTINY-Gastric04: T-DXd vs Ramucirumab + Paclitaxel as Second-line Therapy in HER2+ Unresectable/Metastatic Gastric Cancer/GEJ Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2025

Expires: December 04, 2025

DYNAMIC III
DYNAMIC-III: ctDNA-Guided Escalation of Adjuvant Chemotherapy vs Standard Management in Stage III Colon Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2025

Expires: December 04, 2025

CheckMate 577 OS
CheckMate 577: Final OS Analysis of Adjuvant Nivolumab vs Placebo in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2025

Expires: December 04, 2025

CodeBreaK 101 Cohort G
CodeBreaK 101 Cohort G: Sotorasib + Panitumumab and FOLFIRI in Previously Treated KRAS G12C–Mutated mCRC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2025

Expires: December 04, 2025

CASSANDRA
CASSANDRA PACT-21: Randomized, Phase III Trial of Preoperative Chemotherapy With mFOLFIRINOX or PAXG for Stage I-III PDAC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2025

Expires: December 08, 2025

CheckMate 8HW Update
CheckMate 8HW: Expanded Analyses in Patients With Centrally Confirmed MSI-H/dMMR mCRC From the Phase III Trial of Nivolumab + Ipilimumab vs Nivolumab or Chemotherapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2025

Expires: December 08, 2025

GAIN
GAIN: Phase III Trial of (Neo)Adjuvant Chemotherapy and Radical Liver Resection vs Radical Liver Resection Alone ± Adjuvant Therapy in BTC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2025

Expires: December 08, 2025

ctDNA and Stage III Colon Cancer Prognosis
Phase III N0147 Substudy: Relationship Between Postoperative ctDNA and Patient Outcomes After FOLFOX-Based Adjuvant Therapy for Stage III Colon Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2025

Expires: December 08, 2025

POLCAGB
POLCAGB: Phase II/III Trial of Neoadjuvant Chemotherapy vs Neoadjuvant Chemoradiotherapy in Locally Advanced Gallbladder Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2025

Expires: December 09, 2025

CT041 ST 01
CT041-ST-01: Randomized Phase II Study of Satri-cel vs Physician’s Choice Treatment for Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2025

Expires: December 09, 2025

1801 Part 3B Ph II of Elraglusib
1801 Part 3B: Preliminary Results From a Phase II Study of Elraglusib + Gemcitabine/nab-Paclitaxel (GnP) vs GnP in Previously Untreated mPDAC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2025

Expires: December 10, 2025

Activities

ARCHES 5 Year OS
ARCHES: Post Hoc Analysis of 5-Yr OS Outcomes for Phase III Trial of Enzalutamide + ADT vs Placebo + ADT in Patients With mHSPC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 01, 2025

Expires: November 30, 2025

EV 302 Responder Analysis
EV-302/KEYNOTE-A39: Exploratory Analysis of Responders to Enfortumab Vedotin + Pembrolizumab vs Chemotherapy for Previously Untreated Advanced or Metastatic Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2025

Expires: December 04, 2025

Metacure B2 Cohorts
Metacure (B2 Cohorts): Phase II Trial of Intensified Hormonal Blockade With SBRT in Oligometastatic Castration-Sensitive Prostate Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2025

Expires: December 08, 2025

NIAGARA
NIAGARA: Exploratory ctDNA Analysis in Patients With MIBC Who Received Neoadjuvant Chemotherapy With or Without Durvalumab
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2025

Expires: December 09, 2025

JAVELIN Bladder Medley
Phase II JAVELIN Bladder Medley: Interim Analysis of 1L Maintenance Therapy With Avelumab + Sacituzumab Govitecan vs Avelumab for Advanced Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 10, 2025

Expires: December 09, 2025

Activities

ASC2ESCALATE
ASC2ESCALATE: Phase II Trial of Asciminib in Patients With CML-CP After 1 TKI
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 02, 2025

Expires: December 01, 2025

ASC4START
ASC4START: Phase IIIb Trial of Asciminib vs Nilotinib in Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2025

Expires: December 05, 2025

ctDNA MRD
Prognostic Value of ctDNA-MRD by PhasED-Seq at the End of First-line Treatment for DLBCL in a National Cohort
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2025

Expires: December 08, 2025

Events

Live Event
Conference to Clinic - Bridging Lung Cancer Discoveries to Practice
Congratulations: You achieved a completion on 04/09/2022

You can enroll in the following live event(s) on this topic.

Activities

TROPION-Lung02
TROPION-Lung02: Phase I Study of First-line Datopotamab Deruxtecan + Pembrolizumab ± Platinum Chemotherapy in Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2025

Expires: December 02, 2025

HERTHENA Lung02
HERTHENA-Lung02: Phase III Trial of Patritumab Deruxtecan (HER3-DXd) vs Chemotherapy in EGFRm Advanced NSCLC After a 3rd-Generation EGFR TKI
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2025

Expires: December 02, 2025

SACHI
SACHI: Phase III Trial of Savolitinib + Osimertinib vs Chemotherapy in EGFR-Mutant, MET-Amplified Advanced NSCLC After an EGFR TKI
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 03, 2025

Expires: December 02, 2025

SAVANNAH Randomized Subset
SAVANNAH Subset: Savolitinib ± Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2025

Expires: December 03, 2025

ALNEO
ALNEO: Phase II Trial of Perioperative Alectinib in Potentially Resectable Stage III ALK-Positive NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 04, 2025

Expires: December 03, 2025

Beamion LUNG 1 PRO
Beamion LUNG-1: Patient-Reported Outcomes With Zongertinib for Previously Treated Advanced HER2-Mutant NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2025

Expires: December 04, 2025

IMforte
IMforte: Phase III Trial of Lurbinectedin + Atezolizumab vs Atezolizumab as First-line Maintenance Therapy in ES-SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2025

Expires: December 04, 2025

NeoADAURA
NeoADAURA: Neoadjuvant Osimertinib ± CT vs CT Alone in Resectable EGFRm NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2025

Expires: December 05, 2025

ACHILES
ACHILES: Randomized Phase II Study of Atezolizumab vs Observation After Chemoradiotherapy for Limited-Stage SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2025

Expires: December 05, 2025

Zipalertinib for EGFR ex20ins Mutated NSCLC
REZILIENT1: Zipalertinib in Patients With EGFR ex20ins–Mutated NSCLC After Prior Platinum-Based Chemotherapy ± Amivantamab
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 09, 2025

Expires: December 08, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Breast Cancer: Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.
Lung Cancer: Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.
Lymphoma and Leukemia: Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Genitourinary Cancer: Supported by an educational grant from Astellas.
Gastrointestinal Cancer: Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Astellas

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

PharmaMar

Stemline Therapeutics, Inc.